Skip to main content
. 2020 Aug 17;15(8):e0231234. doi: 10.1371/journal.pone.0231234

Fig 8. Fc-GDF15–treated obese ZSF1 rats demonstrated improved parameters of cardiac function and increased exercise capacity.

Fig 8

Twelve weeks of Fc-GDF15 treatment decreased heart weight (A); decreased left ventricular (LV) mass (B), cardiac output (C), stroke volume (D), and ejection fraction (E) but not heart rate (F). Fc-GDF15–treated obese ZSF1 rats demonstrated improved exercise capacity during treadmill exercise by increased length of time to exhaustion (G) and running distance (H). Stars (*) indicate significance (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001) by unpaired two-tailed t test. Parameters of cardiac function were evaluated in 15 vehicle-treated obese rats and in 12 Fc-GDF15–treated obese rats. Exercise capacity test was performed in 11 rats treated with vehicle and in 8 rats treated with Fc-GDF15.